ImmuCell (ICCC) vs Virax Biolabs Group (VRAX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmuCell is the larger company by market cap ($99.3 million vs $446,401), about 222.4 times the size. ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -95739.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | VRAX |
|---|---|---|
| Share price | $10.92 | $0.3319 |
| Market cap | $99.28M | $446.40K |
| 1-day change | -2.41% | -12.89% |
| YTD return | +77.56% | — |
| 1-year return | +133.33% | — |
| 5-year return | +18.70% | — |
| P/E ratio (TTM) | 57.47 | — |
| EPS (TTM) | $0.19 | $-12.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.64M | $6.33K |
| Revenue growth (YoY) | +4.34% | -95.95% |
| Net income (latest FY) | $-1.04M | $-6.06M |
| Gross margin | 41.40% | -838.21% |
| Operating margin | 5.97% | -97344.76% |
| Net margin | -3.76% | -95739.17% |
| 52-week high | $12.10 | $21.75 |
| 52-week low | $4.67 | $0.293 |
| Distance from 52-week high | -9.75% | -98.47% |
| Average volume | 13.44K | 360.62K |
| Shares outstanding | 9.09M | 1.34M |
| Employees | 73 | 26 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ImmuCell is about 222.4 times larger than Virax Biolabs Group by market value ($99.28M vs $446.40K).
- ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -95739.2 cents for Virax Biolabs Group.
- ImmuCell grew revenue faster in its latest fiscal year (+4.34% vs -95.95%).
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Virax Biolabs Group
VRAX stock →Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 26 employees
ICCC vs VRAX FAQ
Which is bigger, ImmuCell or Virax Biolabs Group?
ImmuCell (ICCC) is larger, with a market capitalization of $99.28M compared with $446.40K for Virax Biolabs Group (VRAX).
Are ImmuCell and Virax Biolabs Group in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.